10-Q · May 13, 2026
Spruce Biosciences reported a disappointing first quarter for 2026, with no revenue generated and an EPS of -8.94, significantly worse than the estimated EPS of -7.32. The company continues to incur substantial net…
Earnings analysis · 10-Q
SPRB earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Spruce remains a development-stage biotechnology company with no product revenue disclosed and substantial losses: Q2 2026 net loss was $16.2 million, or $(6.68) per diluted share, while six-month net loss rose to $28.5…
Read full summary
Spruce remains a development-stage biotechnology company with no product revenue disclosed and substantial losses: Q2 2026 net loss was $16.2 million, or $(6.68) per diluted share, while six-month net loss rose to $28.5 million from $16.1 million year over year. Liquidity improved to $96.3 million of cash, supplemented by $5.5 million of August financing, and management expects funding into the second half of 2027. However, the investment case remains highly dependent on the Q4 2026 TA-ERT BLA and confirmatory-study milestones, with material regulatory, manufacturing, financing, tariff, and clinical-safety risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-6.68
What stood out
-
Cash Position Supported by New Financing
Cash and cash equivalents were $96.3 million as of June 30, 2026. The company also received $5.5 million of gross proceeds from an August 2026 private placement.
-
TA-ERT Regulatory Milestones Remain Planned
Management intends to submit the TA-ERT BLA for MPS IIIB in Q4 2026 and potentially launch in mid-2027 if FDA approval is received.
-
Limited Reported Interest-Rate Sensitivity
The filing states that a hypothetical 1% change in interest rates would not have a material effect on the financial statements as of June 30, 2026 and December 31, 2025.
-
Disclosure Controls Remain Effective
Disclosure controls and procedures were deemed effective as of June 30, 2026, and there were no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
What to watch
-
Losses and Cash-Burn Requirements Persist
The company reported a Q2 2026 net loss of $16.2 million, or $(6.68) per diluted share, and six-month net losses increased to $28.5 million from $16.1 million in the comparable 2025 period. The accumulated deficit was $317.7 million as of June 30, 2026.
-
Additional Financing May Be Required
The company expects to require substantial additional financing despite $96.3 million of cash at June 30, 2026. The Avenue Loan Agreement provides access to term loans of up to $50.0 million, but availability is subject to achievement of regulatory milestones.
-
Tariffs Could Raise Development Costs
The updated trade-risk disclosure states that tariffs of up to 100% on certain patented pharmaceuticals and associated ingredients are scheduled to become effective September 29, 2026, unless reduced, modified, or terminated. The company expects tariffs to increase research and development expenses and potentially disrupt its supply chain.
-
Accelerated Approval and CMC Execution Risk
Accelerated approval remains uncertain: the planned confirmatory trial is described as a placebo-controlled five-year study in 14 patients, and the FDA requires one drug-product PPQ batch at BLA submission plus data from a second batch before midcycle review.
-
Clinical Safety Profile Requires Monitoring
TA-ERT safety data include vomiting in 22 participants (100%), pyrexia in 20 (90.9%), and four (18%) treatment discontinuations. Although three (14%) discontinuations were attributed to hydrocephalus, safety events could delay approval or limit commercialization.
-
Single-Source Manufacturing Concentration
The company relies on a single-source manufacturer for drug product and a single-source manufacturer for drug substance, while APIs are manufactured in South Korea and China. Supply disruptions or regulatory issues at these sources could delay clinical or commercial production.
Management's outlook
No numeric revenue or EPS guidance was provided. Management intends to submit the TA-ERT BLA and initiate the TrAnsform confirmatory study in Q4 2026, with a potential commercial launch in mid-2027 if FDA approval is received. Management expects current cash to fund planned operations and debt obligations into the second half of 2027.
Earlier filings 4
10-K · March 9, 2026
Spruce Biosciences reports robust long‑term clinical data for its lead candidate TA-ERT (e.g., CSF HS-NRE decreased 91.5 ng/mL at 240 weeks, p<0.0001) and confirmed regulatory support for an accelerated approval…
10-Q · May 6, 2025
Spruce reported Q1 2025 collaboration revenue of $0 and a net loss of $14,041 (net loss per share $0.32). Cash and cash equivalents declined to $25,615 versus $38,753 at year-end, and management states that $25.6…
10-Q · November 12, 2024
Spruce reported Q3 collaboration revenue of $602,000 (down from $3,073,000 a year ago) and GAAP net loss of $8.7M (net loss per share $0.21), an improvement versus Q3 2023 net loss of $12.4M (EPS -$0.30). Operating…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.